Member Info for akramms

Related links:

http://romaniascout.ro/metalnrg-says-exclusivity-period-with-regards-to-planned-romanian-oil-and-gas-concession-stake-has-commenced/

https://www.reuters.com/article/romania-offshore-romgaz/romanias-romgaz-eyes-a-20-stake-in-neptun-deep-offshore-gas-project-idUSL8N2AI20N

Exploration Permit Tracking for WA-481-P

https://neats.nopta.gov.au/ApprovalTracking

Under Screening

RTO Coming

Bonds Extended 6 months

The below should have been done, we are awaiting news on this and further possible contracts in different sectors that will benefit from the sterling engine

13 November 2019

MARINE DEVELOPMENT
Further to the market update on 26(th) April 2019, the Company is pleased to announce that it has taken further steps in applying the Stirling engine application, as developed by the Company for its mCHP boilers, in diversified sectors. To this end, the Company has been invited to demonstrate its Stirling technology to a large scale Swedish Marine engine manufacturer with a view to initiating the successful design, development and testing to produce a unit application for the marine and shipping industry; if successful, such application could generate a significant contact for the Company. To assist in achieving this, the Inspirit team will be demonstrating a 3D model of the redesigned engine and application during January 2020.

POLISH PARTNER COLLABORATION
In addition to the above, the Company has also been in discussions with other parties for the application of the Stirling engine technology and these sectors including solar, renewable and refrigeration and this is a reflection on the wealth of expertise within the Company in relation to the Sterling engine technology.

https://www.lse.co.uk/rns/INSP/update-on-product-application-and-the-mchp-boiler-zqi1139djrttvqx.html

Final results well overdue,

Toople PLC Final results for the year ended 30 Sept 2018 were announced 18/12/2018

This year which ended 30 Sep 2019, they've had over 4 months now to announce results, March may be the end date but then they have to give time for AGM meetings....

End of March will be their Interrims.

No news since September.

Results should be out this week, month end.

Market Cap only 1.8m

They announced new order monthly up until August time, then we stopped providing any RNS's. They are definitely keeping thing under wraps. A Telecom provider that has 1000's of customers monthly.

Last RNS
"The Company, which is debt free, has enjoyed strong growth in July and August, traditionally seasonally affected, adding 1,300 and 1,000 new customer orders respectively in these months. The Board expects these new customer orders to deliver additional revenues over and above the GBP500,000 incremental revenues arising from the contracts signed in May 2019."

https://uk.advfn.com/stock-market/london/toople-TOOP/share-news/Toople-PLC-Trading-Update/80739578

Can't wait for Results.

Something Leaked?

Same as last year in December

Should be out soon.

CCS1477: a first-in-class small molecule to treat prostate and other cancers

https://www.cellcentric.com/updates/press-releases/

https://www.cellcentric.com/updates/press-releases/cellcentric-starts-dosing-patients-blood-cancer-tr/

https://www.cellcentric.com/updates/press-releases/cellcentric-enters-clinic-first-class-p300cbp-inhi/

https://www.cellcentric.com/updates/press-releases/cellcentric-raises-26-million-take-first-class-p30/

https://twitter.com/CellCentric

Merck receives FDA approval for Ebola vaccine

https://www.reuters.com/article/us-health-ebola-merck-co/merck-receives-fda-approval-for-ebola-vaccine-idUSKBN1YO06U

https://www.cio.com/article/3489757/merck-prescribes-ai-for-supply-chain-complexity.html

Merck & Co’s Keytruda shows promise with prostate cancer ‘super responders’
....
"Testing for the presence of the PD-L1 biomarker on cancer cells was not enough to predict who responded, however.

The next stage of research will involve trying to find a test that better predicts which patients will respond, with the DNA repair pathway being an obvious candidate for further investigation."

https://pharmaphorum.com/news/merck-cos-keytruda-shows-promise-with-prostate-cancer-super-responders/

Prostate cancer ‘super responders’ live for two years on immunotherapy
...
"Identifying better tests to pick out who will respond best will be critical if pembrolizumab is to become a standard part of prostate cancer treatment."

'Tremendous benefits for some patients'
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:
...

“Immunotherapy has had tremendous benefits for some cancer patients and it’s fantastic news that even in prostate cancer, where we don’t see much immune activity, a proportion of men are responding well to treatment.

“A limitation with immunotherapy is that there’s no good test to pick out those who are most likely to respond. It’s encouraging to see testing for DNA repair mutations may identify some patients who are more likely to respond, and I’m keen to see how the new, larger trial in this group of patients plays out.”

https://www.icr.ac.uk/news-archive/prostate-cancer-super-responders-live-for-two-years-on-immunotherapy

The Oxford AHSN has provided us with feedback from medical oncologists and been a gateway into the NHS. Market access has been paramount in the adoption of the personalised dosing app and has enabled us to speak to clinicians we otherwise would not have had access to.

http://www.ahsn-nenc.org.uk/wp-content/uploads/2019/09/The_Innovators_Expo_WEB-1.pdf

https://www.ahsnnetwork.com/case-study/personalised-oncology-company-leverages-199000-from-innovate-uk-in-partnership-with-the-oxford-ahsn

https://www.proactiveinvestors.co.uk/companies/news/223444/physiomics-virtual-tumour-software-starting-to-gain-traction-in-world-of-oncology-223444.html

Market Cap only £0.7m

$10m+ revenue on trading gold for last two years

In Profit for last two years, however small, more companies on AIM do not even show profit.

$600k to be received in next 6 months, $50,000 received. PLUS $400k to be received in profits from Hourondas over the next two years. This alone makes up the Market Cap.

"Wishbone also said it is “hopeful” that the expansion of its operations in Hong Kong will increase at a greater rate once instability in the region connected to recent protests “settles down”, while the firm is also planning to begin operations in Europe by the end of December, which it expects to have a “positive impact” on turnover and profitability"

Share consolidation will not have an impact on shareholders, value of their shares will be the same.

https://www.proactiveinvestors.co.uk/companies/news/909556/wishbone-gold-shines-as-profits-rise-in-latest-full-year-909556.html

On 18 August 2017, a total of 146,060,843 warrants were issued to new investors and
advisers. The warrants are exercisable at a price of 3.2 pence per share and are
exercisable at any time up to 20 August 2019 (rebased as 14,606,084 warrants
exercisable at 32 pence per Ordinary Share following the Share Consolidation). The
exercise date of these warrants has been extended to 31 December 2019.

https://www.pembridgeresources.com/component/rsfiles/download?path=Circulars%252FPembridge%2BFinal%2BProspectus%2B-%2B11%2BDecember%2B2019.pdf

Shares in issue: 68,720,947
Current Price: 14p
MC: £9,620,932

11 December 2019

Pembridge Resources plc

Publication of Prospectus and Results of Placing

The Company is pleased to announce today the publication of its Prospectus relating to the placing to certain institutional investors (the "Placing") and Re-admission, and that it has raised a total GBP2,500,000 (net of expenses) (the "Net Placing Proceeds") pursuant to the Placing of 20,800,000 Ordinary Shares (the "Placing Shares") at a price of 12.5 pence per Placing Share. Brandon Hill Capital Limited acted as sole bookrunner in connection with the Placing. The expenses of the Placing will be borne by the Company in full.

Pembridge will use the Net Placing Proceeds (GBP2.5 million) and the proceeds of Facility A of the Convertible Loan Agreement, as announced on 30 October 2019, (GBP1.0 million) to loan Minto Explorations Limited ("Minto"), GBP2.3 million, to be held in restricted cash for collateral towards a surety bond, and the remainder will be allocated towards general and administrative functions at its office in London and to cover the costs of Re-admission.

In accordance with the FCA's Disclosure Guidance and Transparency Rules (the "DTRs"), the Company hereby confirms that at the time of Re-admission, the Enlarged Issued Share Capital will comprise in aggregate 68,720,947 Ordinary Shares in issue, which includes 22,384,925 existing Ordinary Shares in issue as at the date of this announcement, 25,536,021 Other Subscription Shares and 20,800,000 Placing Shares, none of which are held in treasury. Therefore, following Re-admission the total number of voting rights in the Company will be 68,720,947.

The above figure of 68,720,947 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the DTRs.

Applications will be made for the Enlarged Issued Share Capital to be admitted to the Official List of the FCA by way of a Standard Listing and to trading on the Main Market of the London Stock Exchange. It is expected that Re-admission will become effective, and that unconditional dealings in the Ordinary Shares will commence, at 8:00 a.m. on 16 December 2019.

https://www.lse.co.uk/rns/PERE/publication-of-prospectus-and-results-of-placing-yk885yyclw11yru.html

4 December 2019

Minto Receives Second Revenue Payment of US$3.7m

London, United Kingdom - Pembridge Resources plc (LSE: PERE) ("Pembridge" or the "Company") is pleased to announce that further to the restart of operations on 15 October 2019 and first revenue of US$3.4m received on 6 November 2019, pursuant to the offtake agreement between Sumitomo Canada Limited ("Sumitomo") and Minto Explorations Ltd ("Minto") dated 22 July 2019 (the "Offtake Agreement"), Minto has received a 90% provisional payment ("Advanced Payment") of US$3.7m for the copper concentrate produced during the month of November 2019 ("Second Revenue").

Highlights

· 1,793 dry metric tonnes of concentrate was produced during November 2019

· Second Revenue received by Minto of US$3.7m from Sumitomo

· Sales includes content for copper, gold and silver in concentrate

Under the terms of the Offtake Agreement, an Advanced Payment has been made by Sumitomo to Minto for 90% of the estimated value of concentrate produced at the Minto mine during the month of November 2019. The final, balancing payment ("Final Invoice") will be paid on delivery to Japan, subject to the quotation period as per the terms of the Offtake Agreement. The Final Invoice will consist of the remaining 10%, plus or minus any commodity price changes to the Advanced Payments made, less accrued interest. Transportation and shipping of the copper concentrate is expected to commence in early Q1 2020.

In addition to the copper revenue, the Advance Payments include precious metals credits and therefore Minto receives 90% of the revenue from the copper, gold and silver due under the terms of the Offtake Agreement.

Gati Al-Jebouri, Chief Executive Officer and Chairman of the Board of Pembridge stated:

"This payment, for production in November 2019, is the second monthly Advanced Payment made to Minto from Sumitomo, bringing total payments received to over US$7.0m since Minto recommenced production 7 weeks ago. It proves the operation's ability to generate steady cash flow as operations ramp up. It is the objective of Minto mine management, with the oversight from Pembridge, to ensure that production continues to grow while ensuring an efficient and cost-effective operation."